Efficacy

Portrazza (necitumumab) Efficacy in Lung Cancer

Portrazza (necitumumab) is a monoclonal antibody designed to target and block the activity of the epidermal growth factor receptor (EGFR), which is known to play a role in the growth and spread of cancer cells. It is specifically approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Clinical trials have demonstrated that necitumumab, when added to chemotherapy, can improve overall survival in this patient population compared to chemotherapy alone. However, it is important to note that Portrazza is not indicated for the treatment of patients with non-squamous NSCLC.

The efficacy of Portrazza was established in a multicenter, randomized, open-label clinical trial, where patients who received necitumumab in combination with gemcitabine and cisplatin had a median overall survival of 11.5 months compared to 9.9 months for those who received chemotherapy alone. This improvement in survival was statistically significant, indicating that Portrazza can offer a meaningful benefit for patients with metastatic squamous NSCLC when used as part of a first-line treatment regimen.

Lorviqua (lorlatinib) Efficacy in Lung Cancer

Lorviqua (lorlatinib) is a third-generation anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of patients with ALK-positive metastatic NSCLC. It is designed to target and inhibit the activity of the ALK protein, which can drive the growth of cancer cells in some lung cancers. Lorlatinib has shown high efficacy in patients who have progressed on prior ALK inhibitors, indicating its potency against ALK-positive NSCLC, including those with central nervous system (CNS) metastases.

The efficacy of Lorviqua was demonstrated in a non-randomized, dose-ranging and activity-estimating, multi-cohort, multicenter study. Patients treated with lorlatinib showed a high overall response rate (ORR), with particularly notable activity in the CNS. The ORR for patients who had received at least one prior ALK inhibitor was significant, and the duration of response (DOR) was also clinically meaningful. These results underscore Lorviqua's role as an effective treatment option for patients with ALK-positive metastatic NSCLC, especially after the failure of other ALK inhibitors.